Teaching cancer imaging in the era of precision medicine: Looking at the big picture

The role of imaging in cancer diagnosis and treatment has evolved at the same rapid pace as cancer management. Over the last twenty years, with the advancement of technology, oncology has become a multidisciplinary field that allows for researchers and clinicians not only to create individualized treatment options for cancer patients, but also to evaluate patients\u27 response to therapy with increasing precision. Familiarity with these concepts is a requisite for current and future radiologists, as cancer imaging studies represent a significant and growing component of any radiology practice, from tertiary cancer centers to community hospitals. In this review we provide the framework to teach cancer imaging in the era of genomic oncology. After reading this article, readers should be able to illustrate the basics cancer genomics, modern cancer genomics, to summarize the types of systemic oncologic therapies available, their patterns of response and their adverse events, to discuss the role of imaging in oncologic clinical trials and the role of tumor response criteria and to display the future directions of oncologic imaging

Pathologic response rates after neoadjuvant therapy for sarcoma: A single institution study

(1) Background: Pathologic necrosis of soft tissue sarcomas (STS) has been used to determine treatment response, but its relationship to neoadjuvant treatments remains indeterminate. In this retrospective, single institution study, we hypothesized that neoadjuvant chemoradiation (NA-CRT) yields higher rates of pathologic complete response (pCR) than neoadjuvant radiation (NA-XRT) or chemotherapy (NA-CT) alone. (2) Methods: Patients with extremity STS between 2011–2020 who received neoadjuvant treatment were included. pCR was defined as percent necrosis of the surgical specimen greater than or equal to 90%. (3) Results: 79 patients were analyzed. 51.9% of the population were male with a mean age of 58.4 years. 49.4% identified as Non-Hispanic White. Twenty-six (32.9%) patients achieved pCR while 53 (67.1%) did not. NA-CT (OR 15.82, 95% CI = 2.58–96.9, p = 0.003 in univariate (UVA) and OR 24.7, 95% CI = 2.88–211.2, p = 0.003 in multivariate (MVA), respectively) and NA-XRT (OR 5.73, 95% CI = 1.51–21.8, p = 0.010 in UVA and OR 7.95, 95% CI = 1.87–33.7, p = 0.005 in MVA, respectively) was significantly associated with non-pCR when compared to NA-CRT. The analysis also demonstrated that grade 3 tumors, when using grade 2 as reference, also had significantly higher odds of achieving pCR (OR 0.23, 95% CI = 0.06–0.80, p = 0.022 in UVA and OR 0.16, 95% CI = 0.04–0.70, p = 0.015 in MVA, respectively). (4) Conclusion: NA-CRT yields superior pCR compared to other neoadjuvant regimens. This extends to higher grade tumors

MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results

ObjectivesBecause size-based imaging criteria poorly capture biologic response in desmoid-type fibromatosis (DF), changes in MRI T2 signal intensity are frequently used as a response surrogate, but remain qualitative. We hypothesized that absolute quantification of DF T2 relaxation time derived from parametric T2 maps would be a feasible and effective imaging biomarker of disease activity.MethodsThis IRB-approved retrospective study included 11 patients with DF, managed by observation or systemic therapy, assessed by 3T MRI. Tumor maximum diameter, volume, and T2-weighted signal intensity were derived from manual tumor segmentations. Tumor:muscle T2 signal ratios were recorded. Two readers measured tumor T2 relaxation times using a commercial T2 scanning sequence, manual ROI delineation and commercial calculation software enabling estimation of reader reliability. Objective response rates based on RECIST1.1 and best responses were compared between size-based and signal-based parameters.ResultsMedian patient age was 52.6 years; 8 subjects were female (73%). Nine patients with longitudinal assessments were followed for an average of 314 days. Median baseline tumor diameter was 7.2 cm (range 4.4 - 18.2 cm). Median baseline T2 was 65.1 ms (range 40.4 - 94.8 ms, n=11); median at last follow-up was 44.3 ms (-32% from baseline; range 29.3 - 94.7 ms, n=9). T2 relaxation times correlated with tumor:muscle T2 signal ratios, Spearman p=0.78 (p<0.001). T2 mapping showed high inter-reader reliability, ICC=0.84. The best response as a percentage change in T2 values was statistically significant (mean -17.9%, p=0.05, paired t-test) while change in diameter was not (mean -8.9%, p=0.12).ConclusionsAnalysis of T2 relaxation time maps of DF may offer a feasible quantitative biomarker for assessing the extent of response to treatment. This approach may have high inter-reader reliability

Sclerosing angiomatoid nodular transformation of the spleen: multimodality imaging findings and pathologic correlate

Sclerosing angiomatoid nodular transformation of the spleen is a recently recognized benign vascular lesion, characterized microscopically by multiple angiomatoid nodules embedded within a fibrosclerotic stroma. Although its imaging manifestations have been limited in the radiologic literature, features such as low-level increased fluorodeoxyglucose activity on a positron emission tomographic scan, near-complete blending in with normal splenic parenchyma on a delayed-phase image, and the presence of radiating scarring on a magnetic resonance image may suggest the diagnosis. We report here the computed tomographic, magnetic resonance imaging, and positron emission tomographic findings of sclerosing angiomatoid nodular transformation, along with gross and microscopic pathological correlation

Survival to the age of 87 years in a woman with unoperated tetralogy of Fallot

Tetralogy of Fallot is the most common cyanotic congenital heart defect, affecting approximately 2700 infants per year born in the United States. The natural history of the tetralogy reflects the adverse physiologic consequences of the underlying structural abnormalities, with only approximately 3% of uncorrected patients surviving past age 40. In this case report, we report an 87-year-old woman with unoperated tetralogy of Fallot, who we believe to be the oldest and only second octogenarian described in the literature

Value added: functional MR imaging in management of bone and soft tissue sarcomas

MRI plays a crucial role in the initial diagnosis, treatment planning, and long-term management of bone and soft tissue sarcomas. Technological advances have enabled improvements in both delineation of anatomic detail, and in functional imaging techniques that interrogate tissues at the cellular level. This bears particular relevance in sarcomas as morphological parameters alone do not necessarily correlate with treatment response and prognosis. Here, we describe recent developments in advanced MRI techniques, including chemical-shift MRI, diffusion-weighted imaging (DWI), MR spectroscopy (MRS), and dynamic contrast enhanced (DCE) MRI. Chemical-shift MRI allows robust discrimination of marrow infiltrating neoplasms from benign red marrow. DWI reveals tumor cellularity, and aids in distinguishing benign and malignant tumors along with the assessment of treatment response. MRS is technically challenging in the musculoskeletal system, but shows promise as a means to noninvasively assess metabolic aberrations in a variety of sarcomas. DCE is particularly suited to treatment response evaluation, in which traditional size-based assessment criteria may underestimate efficacy in clinical trials. Functional MRI techniques offer novel imaging biomarkers that effectively complement conventional MRI in the assessment of bone and soft tissue sarcomas at all stages of patient care

Pleomorphic hyalinizing angiectatic tumor: imaging findings

Pleomorphic hyalinizing angiectatic tumor (PHAT) is a rare soft tissue tumor of low malignant potential, which most often arises in the lower extremities. To the best of our knowledge, there have been no prior descriptions of the imaging features of this neoplasm. In this case series, we report the imaging findings in three patients. Two patients had a lower extremity subcutaneous PHAT, while the third patient had an intramuscular upper extremity PHAT. While imaging features are variable, a diagnosis of PHAT should be considered when encountering an enhancing, subcutaneous tumor with ill-defined margins, particularly in the extremity